The funding accelerates the development of AMT’s ELANA® Heart Bypass System, a minimally invasive solution designed to replace traditional open-heart bypass surgery, ultimately leading to robot-assisted keyhole surgery compatible with surgical robots from industry leaders.
Paradigm Shift in Cardiac Surgery: Key innovations:
The ELANA® Heart Bypass System will enable surgeons to perform the most state-of-the-art coronary artery bypass grafting (CABG) with arterial (instead of venous) bypass grafts and through small chest incisions without stopping the heart or using a heart-lung machine, which eliminates stroke risks and other complications and reduces postoperative recovery times. This contrasts starkly with conventional methods requiring sternotomy (chest cracking), complex suturing and long recovery times. With these improvements, the system further aims to significantly reduce costs associated with CABG procedures.
The sutureless anastomosis technique utilizes a proprietary clip and an excimer laser to connect blood vessels without manual suturing, enabling precise, rapid, and standardized and reproducible graft integration while minimizing complications.
Additionally, the system achieves over 50% cost reduction when used in a robotic setting. This is driven by shorter operating room times, reduced hospital stays (patients can return home within days), fewer complications, and faster surgeon mastery compared to traditional coronary artery bypass grafting.
“This financing validates our mission to make open-heart bypass obsolete. By enabling same-day discharge bypass procedures, we’re not just improving outcomes – we’re redefining cardiovascular care.”
About AMT Medical:
AMT Medical (est. 2017) is an Ede and Utrecht-based innovator spun out of neurovascular ELANA technology which was earlier brought to the market (CE and FDA) by the AMT team. With 27 employees and ISO 13485-certification, the company holds over 40 patents for its beating-heart surgical platform.
AMT secured $40 million in funding including this Series-B Funding round and several multi-million-euro grants from RvO and the European Innovation Council Accelerator. Collaborations with institutions like St. Antonius Hospital in Nieuwegein, The Netherlands, and Charite in Berlin, Germany, position AMT as a leader in next-generation cardiovascular care with goals of expanding into European and U.S. markets, refining fully endoscopic procedures, and reducing global reliance on open-heart surgeries—potentially benefiting 1 million patients annually.
About Bender Analytical Holding:
BAH is an early-stage VC that supports entrepreneurs driving disruptive innovation across medtech, pharma, biotech and high/deep-tech sectors, with a particular focus on those with international ambitions suitable for Strategic exits. The fund invests in seed capital to help initiate international expansion and continues to support entrepreneurs over the long term through follow-on investments.
